Article

Mathematical modeling suggests improved clinical outcomes of second-generation PARP inhibitors with reduced toxicity

2024-01-30

Abstract excerpt

High-grade serous ovarian cancer (HGSC) is one of the most lethal gynecological cancers. Recent clinical trials have shown the remarkable benefits of maintenance treatment with Poly-ADP Ribose Polymerase inhibitors, particularly in patients with tumors deficient in homologous recombination DNA repair. However, the large Phase III clinical trials are limited in their ability to evaluate various dosages and treatmen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 204f7320-b616-5371-890c-1352a5418b78
DOI: 10.1101/2024.01.29.24301918

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mathematical modeling suggests improved clinical outcomes of second-generation PARP inhibitors with reduced toxicityDOI 10.1101/2024.01.29.24301918Read

Modular mechanistic mathematical models for improved biomarker identification and treatment scheduling in oncologySemantic proximity Read

Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy.Semantic proximity Read

Assessing the Role of Model Complexity in Virtual Clinical Trial OutcomesSemantic proximity Read

Pharmacodynamic model of PARP1 inhibition and global sensitivity analyses can lead to cancer biomarker discoverySemantic proximity Read

Data-Driven Mechanistic Computational Modeling of Human Cell Cycle Phases for Defining Inhibitor Combinations in SilicoSemantic proximity Read

Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXsSemantic proximity Read

Approaches to generating virtual patient cohorts with applications in oncologySemantic proximity Read

Assessing the Role of Patient Generation Techniques in Virtual Clinical Trial OutcomesSemantic proximity Read

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.Semantic proximity Read

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisSemantic proximity Read

Cost-effectiveness of PARP inhibitors for maintenance therapy of patients with a BRCA mutation and primary epithelial ovarian cancer in ChinaSemantic proximity Read

Optimizing bevacizumab dosing in first-line ovarian cancer treatment: The PGOG-ov1 trial.Semantic proximity Read